Communication training for doctors treating large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a communication training program for providers who care for people with large B-cell lymphoma. The goal is to improve how clinicians talk with patients, especially during difficult treatment periods like relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your treating provider is also enrolled in this communication study
- You have large B-cell lymphoma, including related types treated like large-cell lymphoma
- Your illness has relapsed or did not respond within the required treatment timeline
- You are 18 or older, and you are fluent in English (you must choose “very well” or “well”)
- You identify as Black and/or White
- You are not in hospice care, and you are well enough to complete study tasks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This study tests whether a computer-guided treatment plan can work as well as or better than the standard chemo-immunotherapy for large B-cell lymphoma. It uses a special test after the first cycle to decide who needs a more aggressive approach.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.